Clementia Pharmaceuticals

Canada
Maple Bay, British Columbia, Canada, H3Z 2Y5

Company profile

Clementia Pharmaceuticals company profile

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.

Business identity

Contact email
[email protected]
Phone number
(514) 940-3600
Operating status
Active
Company type
For Profit
Revenue range
$1M-$10M
Founded
2010-01-01

Headquarters

Postal code
H3Z 2Y5
Country code
CA
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
5
Total equity funding
$230.5M
Last funding
Post IPO Equity / $138M / 2017-08-02
Last equity funding
Post IPO Equity / $138M
Investors
9
Lead investors
3
Founders
1
Articles
22
Exited on
2017-08-02

Founders and investors

Founders

Clarissa Desjardins

Lead investors

BDC Healthcare VentureNew Enterprise AssociatesOrbiMed

Investors

BDC Venture CapitalEcoR1 CapitalNew Enterprise AssociatesOrbiMedRA Capital Management